ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1612

Prediction of Psoriatic Arthritis Tool (PRESTO): Development and Performance of a New Scoring System for Psoriatic Arthritis Risk

Lihi Eder1, Ker-Ai Lee2, Vinod Chandran3, Jessica Widdifield4, Aaron Drucker4, Christopher Ritchlin5, Cheryl F Rosen4, Richard Cook2 and Dafna Gladman6, 1Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, 2University of Waterloo, Waterloo, ON, Canada, 3Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada, 5Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, 6Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada

Meeting: ACR Convergence 2022

Keywords: Epidemiology, prevention, Psoriatic arthritis, risk assessment, Spondyloarthropathies

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes I: Diagnosis and Disease Activity

Session Type: Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: A simple, scalable tool that identifies psoriasis patients at high risk for developing PsA could improve early detection and facilitate early intervention. Our overall objective is to develop an accurate risk prediction model for the development of PsA and to assess its performance among patients with psoriasis.

Methods: In this longitudinal cohort study we analyzed data from the International Psoriasis and Arthritis Team (IPART) study, a prospective cohort of psoriasis patients without PsA at the time of enrollment. The participants were followed prospectively from 2006 to 2020, and their PsA status was assessed annually by a rheumatologist. Information about their demographics, psoriasis characteristics, co-morbidities, medications and musculoskeletal symptoms was used to develop prediction models for PsA. Penalized binary regression models were used for variable selection while adjusting for psoriasis duration; the stacked LASSO with equal weights was adopted to deal with multiple imputed datasets for incomplete data. Risks of developing PsA over 1- and 5-year time horizons were estimated. Internal validity was assessed using 5-fold cross-validation. Model performance was assessed by the area under the curve (AUC), and calibration plots.

Results: A total of 635 psoriasis patients were analyzed (mean duration of follow up 7.7 years). 51 and 71 patients developed PsA during the 1-year and 5-year periods, respectively. The risk of developing PsA within 1 year was associated with younger age, male sex, family history of psoriasis, back stiffness, nail pitting, level of stiffness, use of biologic medications, global health and pain severity (AUC 72.3, 95% confidence interval ((CI) 65.5, 79.1, Figure 1). The risk of developing PsA within 5 years was associated with morning stiffness, psoriatic nail lesion, psoriasis severity (by PASI), fatigue severity (by FACIT-fatigue), pain severity and use of systemic non-biologic medication or phototherapy (AUC 74.9, 95% CI 69.3, 80.5, Figure 2). Calibration plots showed reasonable agreement between predicted and observed probabilities (Figure 3). The sensitivity and specificity for a 2.5% probability of PsA onset within 1 year were 54.5% and 75%, respectively. The sensitivity and specificity for a 5% probability of PsA onset within 5-years period were 61.1% and 77%, respectively.

Conclusion: The development of PsA within clinically meaningful time frames can be predicted with reasonable accuracy for psoriasis patients. Additional work is underway to validate these models in external cohorts of psoriasis patients.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: L. Eder, AbbVie, Lilly, Novartis, UCB, Pfizer; K. Lee, None; V. Chandran, AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Amgen, Pfizer Inc, UCB; J. Widdifield, None; A. Drucker, None; C. Ritchlin, UCB, AbbVie, Eli Lilly, Pfizer Inc, Novartis, Janssen, Bristol-Myers Squibb; C. Rosen, Eli Lilly, Novartis, Amgen, Bristol-Myers Squibb(BMS), UCB, AbbVie/Abbott; R. Cook, None; D. Gladman, AbbVie, Amgen, Eli Lilly, Janssen, Gilead, Novartis, Pfizer, Bristol-Myers Squibb(BMS), Galapagos, UCB Pharma, Celgene.

To cite this abstract in AMA style:

Eder L, Lee K, Chandran V, Widdifield J, Drucker A, Ritchlin C, Rosen C, Cook R, Gladman D. Prediction of Psoriatic Arthritis Tool (PRESTO): Development and Performance of a New Scoring System for Psoriatic Arthritis Risk [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/prediction-of-psoriatic-arthritis-tool-presto-development-and-performance-of-a-new-scoring-system-for-psoriatic-arthritis-risk/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prediction-of-psoriatic-arthritis-tool-presto-development-and-performance-of-a-new-scoring-system-for-psoriatic-arthritis-risk/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology